CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Fakultas Farmasi Universitas Indonesia; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
ETHAN - ET for Male BC
Conditions: Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma Interventions: Drug: Tamoxifen; Drug: Anastrozole; Drug: Degarelix; Drug: Abemaciclib Sponsors: Jose Pablo Leone; Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Fakultas Farmasi Universitas Indonesia; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
ETHAN - ET for Male BC
Conditions: Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma Interventions: Drug: Tamoxifen; Drug: Anastrozole; Drug: Degarelix; Drug: Abemaciclib Sponsors: Jose Pablo Leone; Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Indonesia University; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
ETHAN - ET for Male BC
Conditions: Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma Interventions: Drug: Tamoxifen; Drug: Anastrozole; Drug: Degarelix; Drug: Abemaciclib Sponsors: Jose Pablo Leone; Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Indonesia University; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
ETHAN - ET for Male BC
Conditions: Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma Interventions: Drug: Tamoxifen; Drug: Anastrozole; Drug: Degarelix; Drug: Abemaciclib Sponsors: Jose Pablo Leone; Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Indonesia University; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
ETHAN - ET for Male BC
Conditions: Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma Interventions: Drug: Tamoxifen; Drug: Anastrozole; Drug: Degarelix; Drug: Abemaciclib Sponsors: Jose Pablo Leone; Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Indonesia University; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
ETHAN - ET for Male BC
Conditions: Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma Interventions: Drug: Tamoxifen; Drug: Anastrozole; Drug: Degarelix; Drug: Abemaciclib Sponsors: Jose Pablo Leone; Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Condition: Breast Cancer Intervention: Drug: Tamoxifen Sponsors: Nalagenetics Pte Ltd; SJH Initiatives; Indonesia University; MRCCC Siloam Hospitals Semanggi Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2022 Category: Research Source Type: clinical trials
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
Conditions: Breast Cancer; Quality of Life Interventions: Radiation: Accelerated Partial Breast Irradiation (APBI); Drug: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene Sponsor: UNC Lineberger Comprehensive Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2022 Category: Research Source Type: clinical trials
